HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and export services, with a "1+2+3+4=1" service system and supply channels for original PCL pellets from multiple well-known brands. As a foreign trade enterprise with over ten years of market experience and technology transformation cooperation with manufacturers, HiSiaddi possesses rich experience in product compliance issues. Below is a case of HiSiaddi addressing PCL pellet compliance challenges.
For more consultation on PCL pellet product compliance issues, please contact HiSiaddi customer service.
HiSiaddi resolves multiple compliance barriers covering MDR, REACH, SCIP and biological certification in one stop
The cooperating customer is Paris Derm Tech SAS, located in the biomedical industrial park on the outskirts of Paris. It is a medium-to-high-end specialized manufacturing enterprise deeply engaged in absorbable medical aesthetic filling microspheres, orthopedic soft tissue repair stents and long-acting sustained-release pharmaceutical carriers in Western Europe. Its finished products are classified as EU Class IIa medical devices, strictly complying with four major access specifications: MDR 2017/745 medical device regulations, REACH chemical control, ISO 10993 biosafety and CLP hazard classification. It has long purchased original European medical-grade PCL pellets with an annual stable total procurement volume of 175 tons, representing a typical high-standard and high-value-added overseas high-end raw material purchaser.
Affected by surging local European chemical raw material prices, extended overseas original manufacturer lead times of over 95 days and geopolitical supply chain fluctuations, the customer finalized a domestic PCL substitution procurement plan. In advance, HiSiaddi screened three matching grades from two leading domestic brands, confirming an initial mass order of 62 tons (18 tons of low-viscosity medical aesthetic grade, 30 tons of medium-viscosity sustained-release grade, 14 tons of high-viscosity orthopedic grade). Before finished production, packaging and shipment from Shanghai Port for export customs declaration, the customer encountered full-chain compliance obstacles: compliance documents provided by original domestic manufacturers failed to meet review requirements of French drug regulators and EU ECHA, featuring five fatal compliance defects: SDS versions incompatible with new EU RoHS, undone SCIP notification for SVHC substances of very high concern, missing CMR hazardous substance testing supporting MDR, incomplete sub-items of ISO10993 biological reports and broken raw material traceability documents. The customer’s legal and quality department issued a notice prohibiting cargo shipment before full compliance document rectification. Failure to complete compliance rectification within the deadline would force return of the entire 62-ton cargo, incurring combined losses exceeding EUR 112,000 including ocean freight deposits, port detention warehousing fees and downstream medical aesthetic order breach compensation, while the planned annual 175-ton procurement framework faced direct cancellation risks.
The two domestic PCL manufacturers could only provide general domestic COA quality inspection reports without a dedicated EU regulation compliance compilation team, lacking familiarity with MDR, SCIP and detailed provisions of the new REACH. They could only cooperate to provide basic raw material formula data without independent capacity to complete full EU compliance rectification. The customer urgently fully entrusted Shanghai HiSiaddi Technology (referred to as HiSiaddi) as a foreign trade compliance service provider. Relying on HiSiaddi’s supporting compliance engineers, third-party testing resources and local EU compliance agent resources, we completed supplementary full-category compliance documents, statutory notifications and correction of document loopholes within 28 working days item by item, enabling smooth customs clearance and entry of goods into France for mass production.
Product information: Medical-grade PCL pellets, HS code 3907999000, vacuum packaging in 25kg sterile cardboard drums lined with aluminum foil, divided into three dedicated medical grades.
SDS provided by original domestic manufacturers were compiled in old national standard formats without 16-item preparation of French-English bilingual versions in accordance with EU 2020/878 new REACH+CLP regulations. Only the main PCL resin was listed in the ingredient column without specifying trace components including polymerization catalysts, processing additives and antioxidants. Incorrect RoHS hazard classification labeling, missing provisions on PCL pellet dust hazards and storage-transport protection led to direct judgment of invalid SDS during pre-review by French customs, preventing export customs declaration and EU import filing.
Pre-screening by third parties detected that antioxidant additives used in domestic PCL production contained partial phthalate derivatives (SVHC list controlled substances) with a homogeneous material content of 0.13% exceeding the statutory threshold of 0.1%. In accordance with REACH regulations and EU Waste Framework Directive WFD, official notification must be completed on the ECHA SCIP system with a unique notification number for annual exports exceeding 1 ton, otherwise products are prohibited from circulation and sales within the EU. Domestic manufacturers lacked EU compliance specialists and had never completed SCIP filing, unfamiliar with IUCLID6 declaration document compilation specifications and unable to independently complete notifications, constituting the largest compliance bottleneck for the entire batch of goods.
In accordance with Clause 10.4 of Annex I of MDR, PCL raw materials applied to human implantation and drug carriers must provide special screening reports for CMR 1A/1B carcinogens and EDC endocrine disruptors with a uniform limit of ≤0.1%. Missing this report would prevent the customer from archiving technical documents for its own medical device CE certification and passing incoming material audits by French drug regulators. Conventional factory outgoing tests of domestic manufacturers only cover physical and chemical indicators including melt flow rate, molecular weight and moisture content without special CMR testing items, failing to provide compliance reports issued by EU-recognized laboratories.
The customer’s products involve direct subcutaneous injection and contact with human soft tissues, requiring complete four-item ISO10993 test reports for PCL raw materials: Part 5 cytotoxicity, Part 10 skin irritation, Part 4 hemolysis and Part 11 acute systemic toxicity. Original manufacturers only provided single cytotoxicity tests without the remaining three tests conducted by EU GLP-certified laboratories, and issuing institutions were not listed on the EU drug regulatory white list, preventing archiving and filing in the customer’s quality system for raw material warehousing.
Dual requirements of MDR and REACH mandate full traceability ledgers covering caprolactone monomer sources, catalyst procurement, polymerization production and pelletizing processing for raw materials. Original manufacturers could only provide finished product outgoing documents without upstream monomer supplier qualifications, incoming COA of additives and batch-by-batch production process records, risking full-batch product recalls upon random traceability inspections by EU drug regulators due to incomplete traceability documents.
HiSiaddi compliance engineers accessed full PCL formula component details and re-prepared French-English dual-version SDS in accordance with the 16 modules of EU 2020/878 regulations:
1. Refine Section 3 ingredient column: Specify accurate contents and CAS numbers of main PCL resin, tin octoate catalyst, medical antioxidants and modified regulators separately;
2. Reclassify dust irritation hazards and transportation-storage risks in accordance with CLP regulations, supplement workshop protection, waste liquid disposal and emergency leakage response clauses;
3. Add REACH and MDR compliance statements and SVHC control explanations in Section 15 of SDS for official compliance archiving, confirmed usable by the customer’s legal department in France and smoothly passing pre-review of domestic customs declaration and French import pre-review.
1. Coordinate upstream PCL manufacturers to fine-tune formulas, replace phthalate-containing antioxidant additives exceeding standards with medical compliant antioxidants. Retesting reduced SVHC-related substance content to 0.078% below the 0.1% control red line, eliminating hidden risks of non-compliance at the source.
2. Relying on HiSiaddi’s cooperating local EU compliance agents, sort out product models, SVHC substance parameters and safe usage instructions, compile declaration dossiers via IUCLID6 software and submit SCIP notifications on the ECHA-REACH IT system, obtaining official SCIP notification codes within 7 working days. Documents were entered into the EU chemical database to meet statutory circulation requirements.
HiSiaddi selected SGS domestic GLP laboratories recognized by EU notified bodies to conduct three special tests for the three PCL grades respectively: CMR carcinogens, EDC endocrine disruptors and heavy metal residues, strictly controlling all restricted substance contents below the 0.1% limit. Test reports with EU-recognized signatures were issued, fully matching the technical document archiving standards of the customer’s MDR medical device CE certification and supplementing mandatory MDR compliance materials.
Coordinate laboratories to conduct sampling and testing in batches, urgently completing three missing tests: skin irritation, hemolysis and acute systemic toxicity. Four complete ISO10993 test reports were collected within 21 working days. Issuing laboratories are listed on the EU drug regulatory white list, available for filing of CE certification technical dossiers for the customer’s medical aesthetic products and meeting incoming material audit standards for implant-grade raw materials.
HiSiaddi stationed on-site staff at PCL manufacturers to assist in sorting upstream supply chain documents: retrieve original manufacturer qualifications of caprolactone monomers, incoming quality inspection sheets of catalysts, batch-by-batch polymerization production process records, pelletizing production inspection ledgers and full-item COA of finished products. Compile Chinese-English-French three-version traceability archives in accordance with French drug regulator formats, forming fully traceable documents covering basic chemical raw materials to finished pellets and supplementing full-chain supply chain compliance weaknesses.
After completion of full compliance document rectification, the 62 tons of PCL were shipped in two batches from Shanghai Port to Le Havre Port, France. French customs completed rapid customs clearance without detention or random inspection relying on revised SDS, SCIP notification codes, CMR test reports and complete biological reports. After raw material warehousing and production launch, the three grades matched the customer’s three production lines for medical aesthetic microspheres, sustained-release pharmaceuticals and orthopedic stents with a stable pass rate above 96.8%, fully matching the performance of imported European raw materials. The customer smoothly delivered downstream medical aesthetic and pharmaceutical orders on schedule, successfully avoiding breach losses of EUR 112,000.
Three months after implementation of the compliance project, Paris Derm Tech from France officially signed a full-year 175-ton medical-grade PCL procurement framework contract with HiSiaddi, adopting the compliance document system established in this project. HiSiaddi conducts pre-review of compliance documents for each subsequent batch of shipments to realize normalized compliance control. Meanwhile, the customer put forward new procurement demands for modified PCL dedicated to absorbable surgical sutures, entrusting HiSiaddi to coordinate raw material selection and pre-compliance pre-review.
After launch of compliant domestic PCL, the customer’s comprehensive raw material unit procurement price decreased by 29.3% compared with original imported European raw materials, saving over EUR 460,000 in annual raw material procurement costs. Meanwhile, domestic delivery cycles were shortened to 28~35 days, completely breaking free from constraints of excessively long lead times of overseas original manufacturers.
Relying on this benchmark PCL compliance breakthrough case for high-end French customers, HiSiaddi leveraged the customer’s industry resources in France to successfully contact three European medical consumable enterprises in Spain and Belgium, replicating the integrated service model of "raw material selection + full-chain compliance agency + export supporting services" and delivering multiple batches of samples and mass orders, forming core competitive advantages distinguishing HiSiaddi from traditional spot traders solely supplying goods without cross-border regulation expertise.
The core pain point of this case lies in the fact that domestic PCL manufacturers excel in product mass production yet generally lack professional capabilities in cross-border regulations including EU MDR, REACH and SCIP, with incomplete supporting services covering compliance document compilation, overseas statutory declarations and EU standard testing. High-end overseas medical material customers are bound by stringent EU medical device regulations, where a single raw material compliance defect may cause detention and return of entire batches of goods. Breaking away from traditional foreign trade supply thinking, HiSiaddi takes compliance services as the starting point to systematically supplement full-chain compliance weaknesses across five dimensions: document revision, formula fine-tuning, official notifications, third-party testing and traceability filing. We not only resolved the customer’s urgent risk of order breach but also opened the compliance channel for domestic medical-grade PCL to enter high-end EU medical material supply chains. Against the backdrop of continuously rising compliance thresholds for global medical raw materials in the post-MDR era, one-stop cross-border compliance services serve as the key starting point for chemical foreign trade to firmly bind high-end overseas customers and build differentiated competitiveness.
For more consultation on PCL pellet product compliance issues, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
